Conexus CEO: AI momentum in pharma isn’t slowing, but maturity is uneven

Pharma and biotech are fielding AI pilots across discovery, clinical and commercial, but the gains still hinge on having the right plumbing, culture and talent. That means integrated platforms, governed data, and trained users. The harder truth: AI tends to magnify dysfunction rather than fix it.